Helius Medical Technologies Inc (OTCMKTS:HSDT) has released positive results to a biotech therapy they have been working on for some time. While the market has slighted them in recent trade, HSDT is up near 40% over the last six months, even with Thursday’s dip.
HSDT released news that their traumatic brain injury (“TBI”) portable neuromodulation stimulator saw positive results in a double-blind trial. A large proportion of TBI patients with chronic balance symptoms are left with limited treatments options, so this option and its success have a legitimate market. Endpoints for effectiveness were assessed using the Sensory Organization Test (SOT), measuring balance using computerized dynamic posturography. A total composite improvement of 15 points from the baseline is ideal. HSDT scored 18 points for 2 weeks and 24 points for 5 weeks.
Helius Medical Technologies Inc (OTCMKTS:HSDT) is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain’s ability to compensate for damage due to trauma or disease. The Company’s PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue.
Find out when HSDT stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
“We are excited to be on the forefront of research that may bring this novel and exciting therapy to patients in need,” said Dr. Alain Ptito, Director of the Department of Psychology of the McGill University Health Centre and Coordinating Principal Investigator for the study. “The investigators and research teams from the Montreal Neurofeedback Center, Orlando Regional Medical Center, Oregon Health and Sciences University, Health Tech Connex, Inc., Virginia Commonwealth University, MedStar National Rehabilitation Hospital and University of Wisconsin – Madison are pleased with the execution of this study and look forward to further analysis and publication of the results.”
“This is a very exciting and promising milestone for our Company, patients and the healthcare community,” added Helius’ CEO, Philippe Deschamps. “Our next steps include compiling the clinical evidence produced from this registrational trial and previous studies investigating the PoNSTM treatment, as well as verifying and validating product design improvements and manufacturing to be included in our regulatory application. We are working to submit our 510(K) application to the U.S. FDA in the first half of 2018, with clearance anticipated in the second half of 2018.”
Helius Medical Technologies Inc (OTCMKTS:HSDT) has a market cap of $284.95M with 95.89M shares out. HSDT represents a niche market but also has legitimate technology on its hands. This device could hit shelves next year and would surely impact their bottom line. Keep this one on your radar. Sign-up for continuing coverage on shares of $HSDT stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $HSDT, either long or short, and we have not been compensated for this article.